Sanofi Joins The Ranks of $35/vial Insulin, Adds New Unbranded Insulin to Product Lineup

Yesterday, Sanofi U.S. made an announcement: Effective on July 1, 2022, the company will lower out-of-pocket cost of insulin for uninsured patients and expand access in underserved communities (in reality, the lower prices are available to anyone including those who have insurance deductibles to satisfy). The press release can be viewed athttps://www.news.sanofi.us/2022-06-29-Sanofi-to-lower-out-of-pocket-cost-of-insulin-for-uninsured-patients-and-expand-access-in-underserved-communities.Sanofi has been a laggard relative to its rivals Lilly and Novo Nordisk. For example, in 2019, both Lilly and Novo Nordisk each announced plans to introduce lower-priced " unbranded " prandial insulin analogue products which are not impacted by PBM rebating. Those efforts have been generally successful in ensuring more widespread affordability (prices are artificially-inflated due to the manner in which pharma commercializes drugs; relying on Pharmacy Benefit Managers [ " PBM ' s " ] to secure an exclusive therapeutic class position on drug formularies). The FTC recently announced a new policy whereby PBM ' s and the drug companies which pay legally-exempted kickbacks in the form of " rebates " for exclusive formulary placement may be in violation of several laws, including Section 5 of the FTC Act, Section 3 of the Clayton Act, Section 2 of the Robinson-Patman Act, and the Sherman Act to name several (see the new policy statement athttps://www.ftc.gov/system/files/ftc_gov/pdf/Policy%20Statem...
Source: Scott's Web Log - Category: Endocrinology Tags: Sanofi Aventis Sanofi-Aventis 2022 drug prices Euro API insulin insulin prices Source Type: blogs